insights_auto
Why is ABVX up 2.33%?
Dive Deeperchevron_right
ABVX:NASDAQ
Abivax SA
$88.52
arrow_upward
+2.33%(+2.01) 1D
Oct 27, 12:27:23 PM GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ABVX...
Open
$86.63
High
$89.40
Low
$86.14
Mkt. cap
6.97B
Avg. vol.
1.34M
Volume
297.15K
52-wk high
$148.83
52-wk low
$69.81
Shares outstanding
87.55M
No. of employees
98
Open
$86.63
High
$89.40
Low
$86.14
Mkt. cap
6.97B
Avg. vol.
1.34M
Volume
297.15K
52-wk high
$148.83
52-wk low
$69.81
Shares outstanding
87.55M
No. of employees
98
News stories
From web sources and news partners
BigGo Finance
·
1 hour ago
Deutsche Bank Says S&P 500's Last 2026 Dip May Be Bottoming as Midterm Tailwind Builds
24/7 Wall St.
·
31 minutes ago
S&P 500 at Midday: Tech Lifts the Index While the Dow Lags
ChartMill
·
1 hour ago
S&P 500 Downward Gap Movers on Oct. 27
KuCoin
·
7 hours ago
Calm index, painful "October" for hedge funds _/ Under the s
Profile
Abivax SA is a clinical stage biotechnology company focused on developing innovative treatments that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases.
Abivax has a program in clinical development with its lead drug candidate, obefazimod, to treat ulcerative colitis. Another program in Crohn’s disease is also in preparation and other potential inflammatory indications are being evaluated.
The company’s headquarters are based in Paris, France with a US office in Waltham, Massachusetts. Abivax’s Research and development work is conducted at its research center based in Montpellier, France. Wikipedia
About Abivax SA
CEOMarc de Garidel | Hartmut J. Ehrlich
Employees98
FoundedDec 4, 2013
Headquarters-
SectorBiotechnology
Websiteabivax.com